Cargando…
Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
SIMPLE SUMMARY: Conversion therapy has shown potential for improving the prognosis of patients with unresectable hepatocellular carcinoma (u-HCC). However, information on the characteristics and outcomes of patients undergoing conversion therapy is lacking. We examined 244 patients with u-HCC treate...
Autores principales: | Tomonari, Tetsu, Tani, Joji, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Kawano, Yutaka, Morishita, Asahiro, Okamoto, Koichi, Sogabe, Masahiro, Miyamoto, Hiroshi, Masaki, Tsutomu, Takayama, Tetsuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650115/ https://www.ncbi.nlm.nih.gov/pubmed/37958395 http://dx.doi.org/10.3390/cancers15215221 |
Ejemplares similares
-
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
por: Tomonari, Tetsu, et al.
Publicado: (2022) -
Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020) -
Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020) -
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021) -
Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array
por: Tomonari, Tetsu, et al.
Publicado: (2020)